| Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate JA Reddy, R Dorton, E Westrick, A Dawson, T Smith, LC Xu, M Vetzel, ... Cancer research 67 (9), 4434-4442, 2007 | 231 | 2007 |
| Preclinical antitumor activity of a novel folate-targeted dual drug conjugate CP Leamon, JA Reddy, IR Vlahov, E Westrick, A Dawson, R Dorton, ... Molecular pharmaceutics 4 (5), 659-667, 2007 | 144 | 2007 |
| In vivo structural activity and optimization studies of folate− tubulysin conjugates JA Reddy, R Dorton, A Dawson, M Vetzel, N Parker, JS Nicoson, ... Molecular pharmaceutics 6 (5), 1518-1525, 2009 | 90 | 2009 |
| Folate–vinca alkaloid conjugates for cancer therapy: A structure–activity relationship CP Leamon, IR Vlahov, JA Reddy, M Vetzel, HKR Santhapuram, F You, ... Bioconjugate chemistry 25 (3), 560-568, 2014 | 82 | 2014 |
| Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates CP Leamon, JA Reddy, R Dorton, A Bloomfield, K Emsweller, N Parker, ... Journal of Pharmacology and Experimental Therapeutics 327 (3), 918-925, 2008 | 82 | 2008 |
| Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications CP Leamon, JA Reddy, PJ Klein, IR Vlahov, R Dorton, A Bloomfield, ... Journal of Pharmacology and Experimental Therapeutics 336 (2), 336-343, 2011 | 63 | 2011 |
| Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic JA Reddy, R Dorton, A Bloomfield, M Nelson, C Dircksen, M Vetzel, ... Scientific reports 8 (1), 8943, 2018 | 54 | 2018 |
| Physical activity and bone health. Position stand of the American College of Sports Medicine WM Kohrt, SA Bloomfield, KD Little, ME Nelson, VR Yingling Med Sci Sports Exerc 36, 1985-1996, 2004 | 40 | 2004 |
| Conjugates for treating diseases caused by PSMA expressing cells IR Vlahov, JA Reddy, A Bloomfield, R Dorton, M Nelson, M Vetzel, ... US Patent 9,636,413, 2017 | 34 | 2017 |
| Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs JA Reddy, R Dorton, A Bloomfield, M Nelson, M Vetzel, J Guan, ... Clinical Cancer Research 20 (8), 2104-2114, 2014 | 32 | 2014 |
| Conjugates for treating diseases caused by PSMA expressing cells IR Vlahov, JA Reddy, A Bloomfield, R Dorton, M Nelson, M Vetzel, ... US Patent 9,782,493, 2017 | 28 | 2017 |
| Conjugates for treating diseases caused by psma expressing cells IR Vlahov, JA Reddy, A Bloomfield, R Dorton, M Nelson, M Vetzel, ... US Patent App. 15/245,508, 2016 | 27 | 2016 |
| Conjugates for treating diseases caused by psma expressing cells IR Vlahov, JA Reddy, A Bloomfield, R Dorton, M Nelson, M Vetzel, ... US Patent App. 15/245,512, 2016 | 27 | 2016 |
| Prostate-specific membrane antigen-specific antitumor activity of a self-immolative tubulysin conjugate CP Leamon, JA Reddy, A Bloomfield, R Dorton, M Nelson, M Vetzel, ... Bioconjugate Chemistry 30 (6), 1805-1813, 2019 | 26 | 2019 |
| Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer Y Lu, PJ Klein, E Westrick, LC Xu, HKR Santhapuram, A Bloomfield, ... The AAPS journal 11, 628-638, 2009 | 24 | 2009 |
| Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy CP Leamon, JA Reddy, IR Vlahov, R Dorton, A Bloomfield, M Vetzel, ... Cancer Chemotherapy and Pharmacology 79, 1151-1160, 2017 | 15 | 2017 |
| High levels of expression of P-glycoprotein/multidrug resistance protein result in resistance to vintafolide AD Guertin, J O'Neil, A Stoeck, JA Reddy, R Cristescu, BB Haines, ... Molecular Cancer Therapeutics 15 (8), 1998-2008, 2016 | 14 | 2016 |
| Pre-clinical development of EC1456: a potent folate targeted tubulysin SMDC JA Reddy, A Bloomfield, M Nelson, R Dorton, M Vetzel, CP Leamon Cancer research 74 (19_Supplement), 832-832, 2014 | 14 | 2014 |
| ACSM Position Stand: physical activity and bone health. Medicine and Science adults: cross-sectional data from the Nakanojo Study WM Kohrt, AS Bloomfield, KD Little, ME Nelson, VR Yngling Osteoporos Int 18, 285-93, 2004 | 11 | 2004 |
| PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169. JA Reddy, A Bloomfield, R Dorton, M Nelson, M Vetzel, S Hahn, I Vlahov, ... Cancer research 73 (8_Supplement), 2145-2145, 2013 | 9 | 2013 |
